Trial Title:
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma
NCT ID:
NCT05938387
Condition:
Glioblastoma
Conditions: Official terms:
Glioblastoma
Astrocytoma
Vaccines
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Recruiting
Study design:
Allocation:
Non-Randomized
Intervention model:
Sequential Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Biological
Intervention name:
CV09050101 mRNA vaccine (CVGBM) 12 μg
Description:
CVGBM will be administered as an IM injection.
Arm group label:
Dose escalation: CVGBM Dose Level 1
Intervention type:
Biological
Intervention name:
CV09050101 mRNA vaccine (CVGBM) 25 μg
Description:
CVGBM will be administered as an IM injection.
Arm group label:
Dose escalation: CVGBM Dose Level 2
Intervention type:
Biological
Intervention name:
CV09050101 mRNA vaccine (CVGBM) 50 μg
Description:
CVGBM will be administered as an IM injection.
Arm group label:
Dose escalation: CVGBM Dose Level 3
Intervention type:
Biological
Intervention name:
CV09050101 mRNA vaccine (CVGBM) 100 μg
Description:
CVGBM will be administered as an IM injection.
Arm group label:
Dose escalation: CVGBM Dose Level 4
Intervention type:
Biological
Intervention name:
CV09050101 mRNA vaccine RDE 100 μg
Description:
CVGBM will be administered as an IM injection.
Arm group label:
Dose expansion
Intervention type:
Biological
Intervention name:
CV09050101 mRNA vaccine (CVGBM) 6 μg
Description:
CVGBM will be administered as an IM injection.
Arm group label:
Dose escalation: CVGBM Dose Level -1
Summary:
This study is an open-label, first-in-human, dose-escalation study of CV09050101 mRNA
vaccine (CVGBM) in patients with newly diagnosed "MGMT-unmethylated" Glioblastoma (GBM).
Patients with isocitrate dehydrogenase (IDH)-wildtype astrocytoma with a molecular
signature of "unmethylated" GBM are also eligible.
After surgical resection and completion of radiotherapy for GBM with or without
chemotherapy, patients will receive CVGBM i.e. as monotherapy after radiotherapy with or
without chemotherapy.
The study consists of a dose-escalation part (Part A) which completes enrollment in
February 2024 and a dose-expansion part (Part B) which is anticipated to begin enrolling
in June/July 2024.
Patients will receive a total of 7 administrations of CVGBM on Days 1, 8, 15, 29, 43, 57,
and 71. At the discretion of the Investigator in alignment with the Sponsor's medical
monitor the vaccinations may continue beyond Day 71 every 6 weeks until one year after
the first CVGBM vaccination or upon disease progression or undue toxicity.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Histologically confirmed, newly diagnosed GBM (CNS WHO Grade 4) and IDH-wildtype
astrocytoma with a molecular signature of "unmethylated" GBM.
2. Specific HLA genotype.
3. Gross total or partial resection (i.e., ≥50% of tumor volume resected).
4. Having completed radiotherapy with or without chemotherapy post-surgery at least 2
weeks before study treatment initiation with no signs of disease progression.
Patients must have recovered from any radiotherapy or chemotherapy related side
effects to ≤ Grade 1 (with the exception of ALC and WBC as per eligibility
criteria). Pretreatment (and concomitant treatment) with TTFields therapy for GBM is
allowed.
5. Age ≥18 years.
6. Karnofsky Performance Status (KPS) ≥70%.
7. Life expectancy >6 months.
8. Absolute lymphocyte count (ALC) >0.5 x109/L.
9. Each patient must voluntarily sign and date an informed consent form (ICF) approved
by an Independent Ethics Committee (IEC), prior to the initiation of any
pre-screening, screening or study-specific procedures. Note: Patients will sign a
separate ICF to allow pre-screening/HLA genotyping.
10. Female patients who are post-menopausal (no menses for at least 12 months before the
Screening Visit), or surgically sterile (bilateral tubal ligation, bilateral
oophorectomy, or hysterectomy).
Females of childbearing potential must:
1. Have a negative serum pregnancy test with a sensitivity of at least 25 mIU/mL
within 10 to 14 days, and within 24 hours prior to starting the study treatment
a negative urine pregnancy test.
2. Agree to ongoing pregnancy testing during the study.
3. Use effective contraception at least 28 days before starting study treatment
through to 30 days after the last dose of study treatment. Effective methods of
birth control include:
- combined (estrogen and progestogen containing) hormonal contraception
associated with inhibition of ovulation:
- oral
- intravaginal
- transdermal
- progestogen-only hormonal contraception associated with inhibition of
ovulation:
- oral
- injectable
- implantable
- intrauterine device
- intrauterine hormone-releasing system
- bilateral tubal occlusion
- vasectomised partner + barrier method
- sexual abstinence: Either agree to practice true abstinence, when this is
in line with the preferred and usual lifestyle of the patient. Periodic
abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation
methods) and withdrawal (coitus interruptus), spermicides only and
lactational amenorrhoea method (LAM) are not acceptable methods of
contraception.
11. Male patients, even if surgically sterilized (i.e., status postvasectomy), must:
1. Agree to practice true abstinence, when this is in line with the preferred and
usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation,
symptothermal, post-ovulation methods) and withdrawal (coitus interruptus),
spermicides only and LAM are not acceptable methods of contraception.
2. Agree to practice effective barrier contraception during the entire study
treatment period (e.g., condom) and through to 3 months after the last dose of
study treatment if their partner is of childbearing potential, even if they
have had a successful vasectomy.
Exclusion Criteria:
1. Abnormal (≥Grade 2 NCI-CTCAE v5.0) laboratory values for hematology, liver and renal
function (serum creatinine). The following values apply as exclusion criteria:
1. Hemoglobin <10 g/dL (6.2 mmol/L)
2. White blood cell (WBC) count decrease (<2.5 x109/L)
3. Absolute neutrophil count (ANC) decrease <1.5 x109/L
4. Platelet count decrease <75 x109/L
5. Bilirubin >1.5 x upper limit of normal (ULN according to the performing lab's
reference range), except for patients with Gilbert's syndrome
6. Alanine aminotransferase (ALT) >3 x ULN
7. Aspartate aminotransferase (AST) >3 x ULN
8. Gamma glutamyltransferase (GGT) >2.5 x ULN
9. Serum creatinine increased >1.5 x ULN
2. Tumor biopsy only without gross total or partial resection (i.e., ≥50% of tumor
volume resected).
3. Any prior therapy for GBM (except surgery, radiotherapy with or without chemotherapy
(e.g., temozolomide [TMZ]), TTFields, and steroids) including immunotherapy.
4. Patient on stable or decreasing steroid levels exceeding 10 mg/day prednisone (or
equivalent doses of other steroids) during the last 3 days prior to enrollment.
Expectation that the patient will need steroid doses >10 mg/day prednisone or
equivalent during the next 3 months. Note: Steroid treatment during the study will
be allowed for treatment of cerebral edema or other life-threatening conditions.
5. Active human immunodeficiency virus (HIV) infection (ie, CD4 count below the normal
range) or active Hepatitis B or C infection (i.e., detectable levels of Hepatitis B
DNA or Hepatitis C RNA), or active infections requiring oral or intravenous
antibiotics or that can cause a severe disease.
6. Clinically relevant autoimmune diseases that could impact the assessment of vaccine
safety and efficacy (with the exception of clinically stable thyroid diseases under
medication and vitiligo).
7. Immunosuppression, not related to prior treatment for malignancy. Any medical
condition that requires chronic systemic immunosuppressive therapy including chronic
corticosteroids (except physiologic maintenance/replacement doses), methotrexate,
tacrolimus or any other immunosuppressive agents within 28 days of treatment start,
including, but not limited, to organ transplant-related immunosuppression.
8. Patients with prior hematopoietic stem cell transplantation/prior organ allograft.
9. Any condition that in the judgment of the Investigator is likely to prevent
compliance with study procedures.
10. Patients with impaired coagulation or any bleeding disorder in whom an intramuscular
injection or blood draw is contraindicated.
11. History of myocarditis or pericarditis within the last 3 months or history of
myocarditis or pericarditis following COVID-19 vaccination.
12. Previous mRNA vaccination (e.g., SARS-CoV2) or live attenuated vaccination within 1
month prior to study treatment initiation, other vaccines within 2 weeks prior to
study treatment initiation.
13. Serious illness or condition, which according to the Investigator poses an undue
risk for the patient when participating in the trial, including, but not limited to,
any of the following:
1. Clinically significant cardiovascular disease (myocardial infarction or stroke
within last 6 months, uncontrolled angina within last 3 months, diagnosed or
suspected clinically significant ventricular arrhythmias, ejection fraction
<35%, cerebrovascular event within last 6 months, uncontrolled hypertension
[blood pressure ≥180 mm Hg systolic and 110 mmHg diastolic despite medication])
2. New York Heart Association Class III to IV congestive heart failure
3. Symptomatic peripheral vascular disease
4. Severe pulmonary disease (e.g., severe chronic obstructive pulmonary disease,
pneumonitis or interstitial lung disease)
5. Uncontrolled diabetes (repeated episodes of severe hypo- or hyperglycemia
requiring hospitalization)
6. Severe mental retardation/impairment, psychiatric conditions or substance abuse
resulting in inability to understand informed consent or affecting the
patient's cooperation in the study
7. Severe infection/inflammatory conditions
14. History of other malignancies (except for those which have been adequately treated
and have had no recurrence).
15. Previous anaphylactic or severe allergic reaction to an LNP formulated drug or
vaccine (e.g., Comirnaty or Spikevax) or known allergy to any other component of
CVGBM (e.g., PEG).
16. Allergy to aminoglycoside antibiotics.
17. Pregnant or breastfeeding.
18. Prior (within 30 days prior to study enrollment) or concurrent participation in
another interventional clinical trial studying an investigational product, drug or
treatment regimen. At least 30 days should have passed prior to the first study
treatment with the investigational product (exceptions may be considered on a
case-by-case basis after consultation with the CureVac Medical Director).
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Cliniques Universitaires Saint-Luc
Address:
City:
Woluwe-Saint-Lambert
Country:
Belgium
Status:
Withdrawn
Facility:
Name:
Universitair Ziekenhuis Brussel - PPDS
Address:
City:
Brussel
Country:
Belgium
Status:
Recruiting
Facility:
Name:
CHU de Liège
Address:
City:
Liège
Country:
Belgium
Status:
Recruiting
Facility:
Name:
Universitätsklinikum Freiburg
Address:
City:
Freiburg im Breisgau
Country:
Germany
Status:
Recruiting
Facility:
Name:
University Clinic Heidelberg
Address:
City:
Heidelberg
Country:
Germany
Status:
Recruiting
Facility:
Name:
Universitätsmedizin Mannheim
Address:
City:
Mannheim
Country:
Germany
Status:
Recruiting
Facility:
Name:
Universitätsklinikum Tübingen
Address:
City:
Tübingen
Country:
Germany
Status:
Recruiting
Facility:
Name:
University Clinic Regensburg
Address:
City:
Regensburg
Country:
Germany
Status:
Recruiting
Facility:
Name:
Universitätsklinikum Frankfurt
Address:
City:
Frankfurt am Main
Country:
Germany
Status:
Recruiting
Facility:
Name:
Universitätsklinikum Bonn
Address:
City:
Bonn
Country:
Germany
Status:
Recruiting
Facility:
Name:
University Hospital Essen
Address:
City:
Essen
Country:
Germany
Status:
Recruiting
Facility:
Name:
Universitatsklinikum Leipzig
Address:
City:
Leipzig
Country:
Germany
Status:
Recruiting
Facility:
Name:
Neurosurgical Clinic at the LMU Munich
Address:
City:
München
Country:
Germany
Status:
Recruiting
Facility:
Name:
Erasmusmc Cancer institute
Address:
City:
Rotterdam
Country:
Netherlands
Status:
Recruiting
Start date:
June 1, 2023
Completion date:
March 30, 2026
Lead sponsor:
Agency:
CureVac
Agency class:
Industry
Source:
CureVac
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05938387
